A Study to Determine the Effect of 500 mg Oral Dose of KD025 in Healthy Male and Post-menopausal Female Subjects

NCT05918614 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune System Disorder (Healthy Volunteer)

Interventions

DRUG: Belumosudil mesylate
DRUG: Placebo

Sponsor

Kadmon, a Sanofi Company